Case Report

Tomas Pedraza AndroLean v3 8 weeks

Matt Porter, Nutrition & Hormone Specialist All claims describe the role of dietary androgens affecting normal structure or function in the body. This product is not intended to diagnose, treat, cure or prevent of any disease.

Objective: To report the effects of androgen supplementation on a healthy exercising man. Design: Case report. Subject(s): A 23 year old man. Intervention(s): 8 week supplementation with 200mg of Super-11-DHEA and 200mg of Super-7-DHEA (AndroLean v3 formula) in conjunction with regimented diet and exercise. Outcome measure(s): Body composition measurements; questionnaire; serum and urinary parameters. Results: After 8 weeks the subject experienced a 4.5% reduction in body fat, increased lean body mass, increased strength, and improvements in well being. All serum and urinary parameters stayed within the normal range.
Primordial Performance LLC 13331 NE Whitaker Way Portland, OR 97230, USA Address all correspondence regarding the following publication to eric@primordialperformance.com For sales information, contact : 1-503-841-6702 sales@primordialperformance.com

Conclusion: Supplementing the diet with androgens (AndroLean) may accelerate the growth of muscle and body fat reduction beyond what is obtained from diet and exercise alone.

Introduction: The anabolic action of androgens increases the accrual of lean muscle tissue, while inhibiting the storage of fat tissue. (7, 40-44) Men with low androgens have difculty improving body composition, despite exercise or diet intervention. (45-48, 112-114) In addition, exercise may reduce androgen levels in men, making physiological improvements increasingly difcult. (98) Supplementation with androgens is likely to enhance the response from exercise, and rapidly improve body composition. (45-48) Our case report demonstrates that oral consumption of naturally occuring 11-oxygenated androgens in a lymphatic delivery formula may provide an effective means of increasing anabolism and improving body composition. Case Report: The subject (Tomas Pedraza) was recruited by Primordial Performance to study the effects of the nutritional supplement AndroLean. This 23 year old subject was unemployed and exercised regularly

throughout the week. Due to being unemployed the subject was able to weight train once a day and perform a separate cardiovascular workout sevral hours later. This accommodating schedule allowed the subject to cook all meals and allocate adequate rest for efcient recovery from workouts. The subject used to be much heavier in years past and lost over 60lbs from lifestyle changes alone. After losing an extraordinary amount of weight the subject struggled with body weight uctuations from a highstress environment due to his job title. After cessation of the subjects job, he slowly started exercising again to decrease body fat levels and improve muscle tone. After months of stagnation the subject was enlisted in the AndroLean case study. Methods: The subject completed a pre-cycle questionnaire that covered critical variables such as medication usage, alcohol consumption, dietary practices, sexual function and other life-style factors. The subject was then submitted for an initial pre-screening chemistry panel. Examination of
1

Copyright 2011 Primordial Performance LLC

Case Report

Tomas Pedraza at a glance

Before Chest: 40.5 Waist: 38.5 Biceps: 14.5 Weight: 211lbs. Bodyfat: 22.3% After 8 weeks Chest: 42.2 Waist: 34.7 Biceps: 15.1 Weight: 201 lbs. Bodyfat: 17.9%

Before

After

physical appearance, chemistry panel and questionnaire data suggested that the subject was in good general health. Once the subject was approved for the case study, the nutrition and training protocol was established based on the subjects goals and guidance from the nutrition and hormone specialist.Throughout the study, the nutrition and hormone specialist would follow up with the subject to ensure adhearance to the protocol. Body composition was collected by recording weight and body fat % (7-site pinch test) immediately before and after the cycle. Immdiately prior to the cycle, the subject was submitted for an immediate pre-cycle blood test. If the subject wished to prolong the AndroLean cycle past 30 days, a mid-cycle LH and FSH blood test was performed 24 hours after a dose in order to approve the cycle extension. (See AndroSeries: The effect on natural testosterone production for more information). Immediately following the last day of the cycle, the subject was again submitted for blood tests 24 hours after the nal dose. The subject was instructed to consume a full dose of AndroLean v3 once per day, upon rising, with or without a meal. The full dose contained 200mgs of Super-11-DHEA (17-beta-undecanoyloxyadrenosterone) and 200mgs Super-7-DHEA (3b-acetoxyandrost-5-en-7, 17-dione) in the LiquaVade 24hr Hormone Transport Complex. Nutrition Protocol: The subject followed a 60/25/15 macronutrient plan approximating 2400 calories, which was slightly below maintenance for the subject. His primary protein sources were chicken breasts, tilapia, and whey protein shakes. His primary carbohydrate sources were yams, and Vitargo during his resistance training session. His primary fat sources were what was found naturally in the meat products, and raw almonds. Training Procotol: The subject trained 5 days a week utilizing predominantly free-weight compound movements such as bench presses, deadlifts, military presses, barbell back squats, close grip bench presses and barbell curls. Heavy lifting was performed 5 times per week. Cardiovascular training was performed 5 times a week on a treadmill, Step Mill, or Elliptical machine. Post Cycle Therapy (PCT): Sustain Alpha, EndoAmp Max, Testosterone Conversion Factor-1, and a prototype mineral product was given to the subject immediately after his nal dose of AndroLean. PCT was continued for 28 days to ensure optimal recovery of natural testosterone production.

Discussion: The subject began his AndroLean v3 cycle at a body weight of 211lbs with a body fat measurement of 22.3%. The subject noted an immediate increase in exercise intensity in the rst seven days. After week two, he claimed his muscles felt more pumped with blood. He noticed around week three that physical changes began to manifest in the form of a smaller waist size due the way his pants t around his waist. He noticed a prominent increase in surface vein vascularity through his arms and quadriceps as he weight trained. The subjects body weight stayed consistent throughout the duration of the AndroLean v3 cycle as he lost fat mass and accrued lean body mass simultaneously. The subject reported no signicant side-effects. The subject weighed the exact same as when he started AndroLean v3. His body composition changed favorably as he lost 4.5% body fat. All major muscle groups increased in diameter while his waist measurement decreased. A post cycle blood test revealed all critical bodily functions were in normal ranges. CONCLUSION: This case report demonstrates that the non-estrogenic and non 5a-reduced naturally occuring androgens Super-11-DHEA and Super-7-DHEA used in AndroLean may accelerate the increase in lean body mass and reduction of fat mass in exercising individuals. In this subject, AndroLean improved exercise performance, lowered subcutaneous body fat and increased strength. AndroLean does not seem to overly suppress endogenous hormone production as LH and FSH remained in normal ranges throughout the cycle. This case report suggests that AndroLean is a safe and effective androgen supplement for increasing lean muscle mass while simultaneously decreasing body fat mass.

Copyright 2011 Primordial Performance LLC

Case Report
CHEMISTRY
Parameter w/Reference Values Pre-cycle
5/03/2012 9:01am

Immediate post cycle

6/23/2012 8:29am

30 day post cycle

7/20/2012 8:30am (24hr post dose)

Glucose (mg/dl) 60-99 Calcium (mg/dL) 8.5-10.1 Protein, Total (g/dL) 6.4-8.2 Albumin (g/dL) 3.4-5.0 Globulin (g/dL) 2.4-4.0 Albumin/Globulin (ratio) 1.0-1.8 Kidney & Electrolytes Blood Urea Nitrogen (mg/dl) 6-29 Creatine (mg/dl) 0.70-1.4 eGFR Male (mL/min/1.73m2) Sodium (mmol/L) 136-145 Potassium (mmol/L) 3.5-5.1 Chloride (mmol/L) 98-109 Carbon Dioxide (mmol/L) 21-32

86 9.2 6.8 4.0 2.8 1.4 17 1.12 >=93 138 4.6 104 26

76 8.7 6.3 4.4 1.9 2.3 22 0.95 130 139 4.5 105 24

* * * * * * * * * * * * * * *

Liver AST (U/L) 9-43 ALT (U/L) 12-78 Alkaline Phosphatase (U/L) 50-136 Bilirubin, Total (mg/dL) 0.2-1.0 Urine Leukocytes Nitrate Urobilinogen Protein Ph Blood Specic Gravity Ketone Bilirubin Glucose Hormones Thyroid Stim Hormone (ulU/mL) 0.36-3.74 Progesterone (ng/mL) Luteinizing Hormone (mlU/mL) Folicle Stim Hormone (mlU/mL) Estradiol (pg/mL) Testosterone, Total (ng/dL) 250-1100 Testosterone, Free (pg/mL) 35.0-155.0 DHT (ng/dL) 25-75 DHEA Sulfate (ug/dL) 35-569 * * 7.2 5.3 24 545 86.9 36 * * * 7.7 5.6 27 623 141.4 32 * * * 2.3 3.1 * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * 26 21 53 0.7 24 23 54 0.6 * * * * *

* Not part of the test 1. Original testosterone values where tested to verify subjects had normal HPTA function. 30 day on cycle testosterone levels where not tested as AndroLean is not expected to increase testosterone. 2. We where unable to collect data for this parameter due to nancial limitations.

Copyright 2011 Primordial Performance LLC

Case Report
Parameter w/Reference Values Pre-cycle
5/03/2012 9:01am

Immediate post cycle

6/23/2012 8:29am

30 day post cycle

7/20/2012 8:30am (24hr post dose)

Cardiovasular & Heart Total High Density Lipoprotein (HDL) (mg/dL) >40 HDL2 (mg/dL) >10 HDL3 (mg/dL) >30 Total Low Density Lipoprotein (LDL) (mg/dL) <160 LDL 4+3+2+1 (mg/dL) <100 Lp(a) (mg/dL) <10 lDL (mg/dL) <20 Total Very Low Density Lipoprotein (VLDL) (mg/dL) <30 VLDL1+2 (mg/dL) <20 VLDL3 (mg/dL) <10 Total Cholesterol Triglycerides (mg/dL0 <150 Non HDL Cholesterol Remnant Lipoproteins (mg/dL) <30 Lipoprotein (a) (Lp(a)) (mg/dL) <10 LDL Density (Pattern) Apolipoprotein B (Apo B) (mg/dL) Apolipoprotein A1 (Apo A1) (mg/dL) Apo B/A1 ratio Blood Pressure Hematology WBC (thous/uL) 4.0-11.0 RBC (mil/uL) 4.5-6.0 Hemoglobin (g/dL) 14.0-18.5 Hematocrit (%) 40.8-52.0 MCV (fL) 80.0-100.0 MCH (pg) 26.0-34.0 MCHC (g/dL) 32.0-36.0 RDW (%) 11.5-15.0 Platelets (thous/uL) 150-450 MPV (fL) 7.0-11.0 Neutrophils (%) 43-78 Lymphocytes (%) 19-46 Monocytes (%) 0-9 Eosinophils (%) 0-6 Neutrophil Abs# (thous/uL) 1.5-7.7 Lymphocyte Abs# (thous/uL) 1.0-4.8 Monocyte Abs# (thous/uL) 0.0-0.9 Eosinophil Abs# (thous/uL) 0.0-0.4 5.8 4.61 14.7 43.7 94.8 31.9 33.7 13.7 183 * * * * * * * * * 6.7 4.75 15.3 45.2 95.3 32.2 33.8 13.3 205 * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *

* Not part of the test 1. Original testosterone values where tested to verify subjects had normal HPTA function. 30 day on cycle testosterone levels where not tested as AndroLean is not expected to increase testosterone. 2. We where unable to collect data for this parameter due to nancial limitations.

Copyright 2011 Primordial Performance LLC

Case Report
Additional photos

Before

After

Before

After

Before
Copyright 2011 Primordial Performance LLC

After
5